Anagenex Closes $30 Million Series A Round Led By Catalio To Advance Small Molecule Drug Discovery With A Novel, Directed Evolution Platform
Anagenex Closes $30 Million Series A Round Led By Catalio To Advance Small Molecule Drug Discovery With A Novel, Directed Evolution Platform
06/08/22, 12:00 PM
Location
bostonMoney raised
$30 million
Industry
science and engineering
health care
media and entertainment
Round Type
series a
Anagenex, a pioneering drug discovery company pairing large-scale data generation with machine learning to discover the next generation of small molecule medicines, today announced that it has closed a $30 million Series A financing round led by Catalio Capital Management, with participation from existing investors Lux Capital, Khosla Ventures, Obvious Ventures, Air Street Capital, and Menlo Ventures. Catalio’s George Petrocheilos and Dr. Matthew Hobson will be joining the company’s Board as a Director and Observer respectively. Anagenex will use its Series A funds to further expand its novel data generating platform and build a robust pipeline of programs addressing historically challenging unmet medical needs.
Company Info
Location
boston, massachusetts, united states
Additional Info
Anagenex is a pre-clinical biotechnology innovator advancing drug discovery through its small molecule directed evolution platform. The company’s unique, machine learning-driven technology enables Anagenex to discover first-in-class and best-in-class small molecule medicines addressing historically intractable targets. With a team of highly experienced scientists and engineers, the company has offices in the San Francisco Bay area and Woburn, Mass. Learn more about Anagenex at www.anagenex.com or connect on Twitter and LinkedIn.